Home
PaxVax

PaxVax Market Share Analysis for June 2026

Sản phẩm

Health > Biotechnology and Pharmaceuticals

Domainpaxvax.com

Year Founded2006

Employees201 - 500

Annual Revenue$25M - $50M

PaxVax

PaxVax (including company regionals)

paxvax.com

See more website traffic and engagement information

PaxVax Revenue up to June 2026 is 25M - 50M

revenue generated by PaxVax top domains

PaxVax top domains revenue over 3 years

Revenue for PaxVax top domains

paxvax.com25M - 50M

See more with Sales Intelligence

Total visits to PaxVax's top domains

Understand PaxVax market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in PaxVax's top domains

Analyze PaxVax engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on PaxVax's top domains

See how PaxVax keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

PaxVax top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by PaxVax

These are the website technologies, by industry, used by PaxVax top domains

Social (5)

Instagram

Advertising (3)

DoubleClick

Content Management System (3)

WordPress

Conversion & Analytics (3)

Google Analytics

More Technologies

5

See all

News & Signals from PaxVax

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsEmergent Testing, LLC acquired Paxvax on Jan 1st '18.Emergent acquired PaxVax in 2018 which came with an early-stage Chikungunya vaccine candidate.

NewsPaxvax is developing chikungunya vaccine on Jan 2nd '19.Outside of Themis and Valneva, PaxVax is also working on a chikungunya vaccine and earlier this year picked up an FDA fast track designation for its candidate.

NewsPaxvax partnered with University of California on Jun 1st '14.In June 2014, PaxVax Inc., entered into a research and development collaboration with the University of California to develop a combination vaccine to prevent genital herpes simplex virus infections.